10,480 results on '"Triple Negative Breast Neoplasms"'
Search Results
52. Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
53. Preventive stRategy for IMMU132-relatED AEs in TNBC - PRIMED (PRIMED)
54. Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
55. Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
56. Sitravatinib in Metastatic Breast Cancer
57. A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
58. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
59. Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
60. A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
61. Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
62. Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
63. A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
64. Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)
65. A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
66. VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study
67. Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
68. Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer (ToPCourT)
69. Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)
70. Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer
71. Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA)
72. Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
73. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)
74. A Multicentre Prospective Cohort Study: Intensive Adjuvant Therapy for TNBC With BRCA Gene Mutation
75. QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer (QUEEN-Dream)
76. NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
77. Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)
78. PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC (NeoADAPT)
79. A Study of Tetrathiomolybdate (TM) Plus Capecitabine
80. Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
81. A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
82. STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
83. Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
84. GEN1046 Safety Trial in Patients With Malignant Solid Tumors
85. SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
86. A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
87. Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
88. Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
89. DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)
90. A Study of NX-1607 in Adults With Advanced Malignancies
91. A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
92. Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC (AIDOBE)
93. PRO1184 for Advanced Solid Tumors (PRO1184-001)
94. Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
95. Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
96. A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)
97. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR
98. LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
99. Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
100. Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.